SCN5A Variant E49G
Summary of observed carriers, functional annotations, and structural context for SCN5A E49G. Data combine curated literature, international cohorts, and gnomAD observations.
Estimated LQT3 penetrance
5%
0/10 effective observations
Estimated BrS1 penetrance
6%
0/10 effective observations
Total carriers
0
0 BrS1 · 0 LQT3 · 0 unaffected
Variant features alone are equivalent to phenotyping 0 individuals for Brugada syndrome and 0 individuals for LQT3.
In silico predictors
PROVEAN | PolyPhen-2 | BLAST-PSSM | REVEL | Penetrance Density BrS (%) | Penetrance Density LQT3 (%) |
---|---|---|---|---|---|
NA | NA | NA | 0.52 | 0 | 4 |
PROVEAN scores below -2 suggest deleterious impact. REVEL scores above 0.5–0.75 are often interpreted as likely pathogenic. PolyPhen-2 scores above 0.85 are typically pathogenic. Penetrance density summarises neighbouring residue risk (Kroncke et al. 2019).
Reported carrier data
Source | Year | Carriers | Unaffected | LQT3 | BrS1 | Other | Other Disease |
---|---|---|---|---|---|---|---|
Literature, cohort, and gnomAD | – | 0 | 0 | 0 | 0 | – | |
Variant features alone | – | 15 | 15 | 0 | 0 | – | – |
Totals may differ from individual publications due to duplicate patients removed during curation.
Nearby variants
Neighbouring residues within 15 Ångström provide structural context. Variants listed in the right-most column have been observed clinically or in gnomAD.
Neighbour residue | Distance (Å) | Observed variants |
---|---|---|
34 | 15 | R34C, R34H, |
35 | 14 | G35S, |
36 | 14 | |
37 | 13 | T37A, |
38 | 13 | |
39 | 12 | L39F, |
40 | 11 | |
41 | 11 | |
42 | 10 | |
43 | 9 | R43X, R43Q, |
44 | 8 | |
45 | 8 | G45A, |
46 | 7 | |
47 | 5 | |
48 | 4 | E48K, |
49 | 0 | E49K, |
50 | 4 | |
51 | 5 | A51V, |
52 | 7 | P52H, P52S, |
53 | 8 | R53Q, |
54 | 8 | |
55 | 9 | Q55X, |
56 | 10 | |
57 | 11 | |
58 | 11 | |
59 | 12 | |
60 | 13 | A60P, |
61 | 13 | |
62 | 14 | K62T, |
63 | 14 | K63N, |
64 | 15 | p.L64del, |